Table 2.
• Receptor blockade (H1 antagonists) |
• Cyclic AMP elevation |
• Cyclic GMP/NO (lung, large vessels) |
• PKC inhibition (bovine, porcine EC) |
• Rho and Rho kinase inhibition |
• Inhibition of leucocyte adhesion and activation (anti-LFA-1, anti-ICAM-1) |
• Inhibition of VEGF induced leakage (anti-VEGF antibodies, VEGF receptor tyrosine kinase inhibitor SU5416, Angiopoietin) (tumour vascular bed) |